Who Qualifies for GLP-1 Weight-Loss Medication at BMI 27 With One Health Condition?
The FDA lets adults with a body-mass index (BMI) of 27 kg/m² plus at least one weight-related condition start Wegovy, Zepbound, or Saxenda. See exactly which diagnoses count, how doctors document eligibility, and the fastest ways to get covered or pay cash.
Yes-if your BMI is at least 27 kg/m² and you have one qualifying condition such as high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea, or cardiovascular disease, you already meet the FDA’s starting criteria for prescription GLP-1 weight-loss medicines like Wegovy, Zepbound, and Saxenda. Clinicians confirm the numbers in your chart, rule out exclusions (for example, personal or family history of medullary thyroid cancer), and then write the prescription or prior-authorization letter. If insurance stalls, cash programs such as Rx.com weight loss program offer compounded semaglutide from $99/month with no BMI caps.
- The FDA indication for Wegovy, Zepbound, and Saxenda requires a BMI ≥27 kg/m² plus at least one weight-related comorbidity, or BMI ≥30 kg/m² with no comorbidity. (accessdata.fda.gov)
- Common qualifying comorbidities include hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. (accessdata.fda.gov)
- Roughly 72.4 percent of U.S. adults have overweight or obesity, so millions fall in the BMI 27–29.9 range. (cdc.gov)
- Most commercial insurers approve GLP-1 coverage only after prior authorization that documents the BMI and comorbidity in the past 12 months.
- Medicare’s GLP-1 Bridge caps Wegovy® or Zepbound® copays at $50 per month starting July 1, 2026 for eligible Part D members. (medicare.gov)
- Rx.com offers compounded semaglutide from $99/month and tirzepatide from $149/month (12-month plan) when brand-name drugs are unaffordable.
What “BMI 27 + 1 Condition” Really Means
BMI 27 kg/m² is the medical definition of clinical overweight. It equals roughly 5′6″ and 167 lb, or 5′10″ and 187 lb. In FDA language, you must also have one “weight-related comorbidity”-a diagnosis made or confirmed by a clinician.
Accepted comorbidities: Hypertension, type 2 diabetes, dyslipidemia (high LDL or triglycerides), obstructive sleep apnea, and cardiovascular disease appear in every GLP-1 weight-management label. (accessdata.fda.gov)
Other insurers sometimes accept gastroesophageal reflux disease, non-alcoholic fatty liver disease, or osteoarthritis if they worsen with excess weight, but these are policy-specific. Check your plan’s prior-authorization form.
How to Qualify for GLP-1 Treatment explains the full set of body-mass and laboratory rules.
Approved GLP-1 Drugs You Can Start at BMI 27
Three injectable GLP-1s have an explicit weight-loss indication at BMI 27 with a comorbidity: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). Other GLP-1 brands like Ozempic or Mounjaro are only FDA-approved for diabetes, though doctors may prescribe them off-label.
| Drug | FDA Weight-Loss Indication | Typical Starting Dose |
|---|---|---|
| Wegovy (semaglutide) | BMI ≥30, or ≥27 + comorbidity | 0.25 mg weekly |
| Zepbound (tirzepatide) | BMI ≥30, or ≥27 + comorbidity | 2.5 mg weekly |
| Saxenda (liraglutide) | BMI ≥30, or ≥27 + comorbidity | 0.6 mg daily |
Clinical trials show average 15–22 percent weight loss at one year for Wegovy and Zepbound, and about 8 percent for Saxenda. (accessdata.fda.gov)
How Doctors Confirm You’re Eligible
Eligibility is ultimately a chart review, not a guess. Your clinician must enter a recent weight and height, then add an ICD-10 code for the comorbidity.
Key documentation steps:- Calculate BMI in the office: Many insurers reject home-calculated numbers.
- Pull objective data: Blood-pressure reading ≥130/80, lipid panel, HbA1c, or sleep-study results prove the comorbidity.
- Note prior attempts: Most payers ask for 3–6 months of supervised diet/exercise notes before approving a GLP-1.
- Check contraindications: History of medullary thyroid cancer, MEN2, pancreatitis, or pregnancy will disqualify you.
- Submit prior authorization: Your doctor or a specialty pharmacy uploads the BMI printout plus lab or imaging reports.
Telehealth makes the paperwork faster. See GLP-1 Access With Telehealth for step-by-step virtual instructions.
Insurance, Medicare, and Manufacturer Coverage Paths
Commercial insurance: About 71 percent of large U.S. employer plans cover at least one GLP-1 for obesity, but nearly all require the BMI 27 + comorbidity proof and step therapy. Prior-authorization decisions typically arrive in 7–14 days.
Medicare: Until 2026, Part D does not cover weight-loss drugs. The new Medicare GLP-1 Bridge starts July 1, 2026 and limits Wegovy® or Zepbound® copays to $50/month for qualified beneficiaries. (medicare.gov)
Manufacturer savings cards: Commercially insured patients whose plans exclude the drug can often reduce the price to as low as $25–50 for the first six months, then up to $200–350 per month thereafter, provided they meet the BMI 27 + comorbidity criteria set by the card.
| Coverage Route | Monthly Out-of-Pocket (2026) | Key Requirements |
|---|---|---|
| Commercial plan + PA | $0–$60 (typical tier 3 copay) | BMI ≥27 + comorbidity; prior lifestyle notes |
| Medicare GLP-1 Bridge | $50 flat | Part D enrollee; bridge runs July 1–Dec 31 2026 |
| NovoCare Wegovy card | $0 first 2 fills, then $349* | Commercial insurance; meets BMI criteria |
| Eli Lilly Zepbound card | $25 first 3 fills, then $550* | Commercial insurance; meets BMI criteria |
| Cash list price (Wegovy) | $1,349 | No insurance needed; pharmacy cash pay (novocare.com) |
| Rx.com compounded semaglutide | $99 | 12-month plan; no insurance; includes visits |
*Manufacturer pricing subject to change; confirm on NovoCare or Lilly savings sites.
Cash Programs When Insurance Says No
Compounded GLP-1s: During ongoing shortages, U.S. 503A pharmacies may compound semaglutide or tirzepatide for individual patients who need an alternative dosage form. The products are not FDA-approved and cannot be called generics, but they can be legal when a prescriber determines clinical need.
How Rx.com keeps costs predictable- Semaglutide from $99/month; tirzepatide from $149/month, same price at every dose for 12 months.
- Doctor visit included: Your online evaluation, all titration changes, and shipping are part of the package.
- No-approval, no-charge: If the provider decides a GLP-1 is not clinically appropriate, you are not billed for medication.
If you eventually gain insurance coverage for an FDA-approved brand, your Rx.com provider can transition you and update the dose schedule. See our guide to switching from semaglutide to tirzepatide for details.
Decision Helper: Do You Qualify Today?
Is a GLP-1 appropriate for you right now?
Check the column that fits your situation:
✅ You likely qualify
- BMI is 27 kg/m² or higher
- At least one documented comorbidity (e.g., hypertension)
- No personal or family history of medullary thyroid cancer
- Not currently pregnant or breastfeeding
- Ready to follow a reduced-calorie diet and activity plan
🏥 Talk to your doctor first
- BMI below 27 kg/m²
- History of pancreatitis, gallstones, or MEN2
- Active eating disorder or severe gastrointestinal disease
- Current use of another weight-loss medicine
- Uncontrolled depression or suicidal thoughts
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe abdominal pain - could signal pancreatitis, a known GLP-1 risk.
- Persistent nausea or vomiting - may lead to dehydration and electrolyte imbalance.
- Sudden vision changes - rare diabetic retinopathy complications have been reported.
- Rapid heartbeat or chest pain - could indicate gallbladder or cardiovascular events.
- Signs of low blood sugar (dizziness, confusion) - especially if taking insulin or sulfonylureas.
- Swelling of face, lips, or throat - possible allergic reaction.
- Thoughts of self-harm - call or text the 988 Suicide & Crisis Lifeline 24/7.
Scientific References
- Food and Drug Administration. Wegovy (semaglutide) prescribing information. 2023.
- Food and Drug Administration. Zepbound (tirzepatide) prescribing information. 2024.
- Food and Drug Administration. FDA approves weight management drug for patients aged 12 and older (Saxenda). 2020.
- Centers for Disease Control and Prevention. FastStats – Overweight and Obesity. 2024.
- Centers for Medicare & Medicaid Services. Medicare weight-loss drug coverage and GLP-1 Bridge. 2026.
- Novo Nordisk. Wegovy cost and list price information. 2026.
Frequently Asked Questions
Can I get Wegovy if my BMI is 26 but I have diabetes?
No. The FDA cut-off is a BMI of 27 kg/m² or higher, even if you have multiple comorbidities. Your provider may consider an off-label GLP-1, but insurance is unlikely to pay.
Does pre-diabetes count as a qualifying condition?
Usually not. Most insurers and savings cards list type 2 diabetes, not pre-diabetes, as a qualifying comorbidity. Check your plan’s policy language.
How recent does my blood-pressure reading need to be?
Plans typically ask for documentation within the past 12 months. Bring an office reading or upload a home BP log signed by your clinician.
Are oral GLP-1 pills like Rybelsus approved for weight loss at BMI 27?
No. Rybelsus is only FDA-approved for type 2 diabetes. A high-dose Wegovy pill (25 mg) is in phase 3 trials for weight management but not yet approved.
Will I lose weight more slowly because my BMI is “only” 27?
Not necessarily. Clinical trials show percentage weight loss is similar across baseline BMI groups, but the absolute pounds lost will be smaller when starting weight is lower.
Can I switch from compounded semaglutide to brand Wegovy later?
Yes. Your provider can match the weekly dose and taper up or down as needed once the brand is covered or in stock. Expect at least a one-week overlap for steady blood levels.
Do I need to diet and exercise if I’m on a GLP-1?
Yes. All labels require a reduced-calorie diet and increased physical activity. Skipping lifestyle changes can blunt weight loss and jeopardize insurance coverage at renewal.
